Literature DB >> 16784932

Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass.

Harm H H Feringa1, Jeroen J Bax, Abdou Elhendy, Robert de Jonge, Jan Lindemans, Olaf Schouten, Anton H van den Meiracker, Eric Boersma, Arend F L Schinkel, Miklos D Kertai, Marc R H M van Sambeek, Don Poldermans.   

Abstract

Postoperative cardiac events are related to myocardial ischemia and reduced left ventricular function. The utility of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) for preoperative cardiac risk evaluation has not been evaluated. The objective of this study was to assess whether plasma NT-pro-BNP predicts postoperative cardiac events in patients who undergo major vascular surgery in addition to clinical and dobutamine stress echocardiographic data. One hundred seventy consecutive patients scheduled for major noncardiac vascular surgery were prospectively evaluated by dobutamine stress echocardiographic and NT-pro-BNP measurements. Multivariable logistic regression analysis was performed to evaluate the predictors of cardiac death and nonfatal myocardial infarction during a follow-up of 30-days. Receiver-operating characteristic analysis was performed to determine the optimal cut-off value of NT-pro-BNP to predict outcome. Patients' mean age was 59 +/- 13 years, and 71% were men. The median NT-pro-BNP level was 110 pg/ml (interquartile range 42 to 389). Cardiac events occurred in 2 of 144 patients (1.4%) with NT-pro-BNP <533 pg/ml (i.e., the optimal cut-off value to predict cardiac events) and in 11 of 26 patients (42%) with NT-pro-BNP >or=533 pg/ml (unadjusted odds ratio 52, 95% confidence interval 11 to 256, p <0.0001). After adjustment for cardiac risk factors and dobutamine stress echocardiographic results, NT-pro-BNP remained significantly associated with cardiac events (adjusted odds ratio 17, 95% confidence interval 3 to 106, p = 0.002). In conclusion, in patients scheduled for major vascular surgery, elevated plasma NT-pro-BNP levels are independently associated with an increased risk for postoperative cardiac events. Further studies in a larger number of patients are required to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784932     DOI: 10.1016/j.amjcard.2006.01.058

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms.

Authors:  Chiara Barisione; Silvano Garibaldi; Claudio Brunelli; Manrico Balbi; Paolo Spallarossa; Marco Canepa; Pietro Ameri; Francesca Viazzi; Daniela Verzola; Alessandra Lorenzoni; Riccardo Baldassini; Domenico Palombo; Bianca Pane; Giovanni Spinella; Giorgio Ghigliotti
Journal:  Intern Emerg Med       Date:  2015-10-28       Impact factor: 3.397

2.  Preoperative brain natriuretic peptide (BNP) is a better predictor of adverse cardiac events compared to preoperative scoring system in patients who underwent abdominal surgery.

Authors:  Paolo Mercantini; Salvatore Di Somma; Laura Magrini; Andrea Kazemi Nava; Andrea Scarinci; Marco La Torre; Mario Ferri; Enrico Ferri; Niccolò Petrucciani; Vincenzo Ziparo
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

Review 3.  The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.

Authors:  Lisette M Vernooij; Wilton A van Klei; Karel Gm Moons; Toshihiko Takada; Judith van Waes; Johanna Aag Damen
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

Review 4.  Preoperative cardiac risk assessment for noncardiac surgery in patients with heart failure.

Authors:  Jenica Upshaw; Michael S Kiernan
Journal:  Curr Heart Fail Rep       Date:  2013-06

5.  Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.

Authors:  Yasir AlSiraj; Sean E Thatcher; Ching Ling Liang; Heba Ali; Mark Ensor; Lisa A Cassis
Journal:  J Pharmacol Exp Ther       Date:  2021-03-11       Impact factor: 4.030

6.  Plasma N-terminal pro-B-type natriuretic peptide is predictive of perioperative cardiac events in patients undergoing vascular surgery.

Authors:  Ji Hyun Yang; Jin Ho Choi; Young-Wook Ki; Dong Ik Kim; Duk-Kyung Kim; Jeong Rang Park; Jae K Oh; Seung-Hyuk Choi
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

7.  Utility of B-type natriuretic Peptide for predicting perioperative cardiovascular events in patients without history of cardiovascular disease undergoing major non-cardiac surgery.

Authors:  Sung Eun Kim; Dae-Gyun Park; Jun Hee Lee; Kyoo Rok Han; Dong Jin Oh
Journal:  Korean Circ J       Date:  2011-01-31       Impact factor: 3.243

8.  Comparison of transthoracic echocardiography with N-terminal pro-brain natriuretic Peptide as a tool for risk stratification of patients undergoing major noncardiac surgery.

Authors:  Sung-Ji Park; Jin-Ho Choi; Soo-Jin Cho; Sung-A Chang; Jin-Oh Choi; Sang-Cheol Lee; Seung Woo Park; Jae K Oh; Duk-Kyung Kim; Eun-Seok Jeon
Journal:  Korean Circ J       Date:  2011-09-29       Impact factor: 3.243

9.  Prognostic value of plasma N-terminal pro-B-type natriuretic peptide concentration in patients with normal and impaired left ventricular systolic function undergoing surgery for abdominal aortic aneurysm.

Authors:  Marek Waliszek; Agnieszka Waliszek-Iwanicka; Tomasz Grycewicz; Piotr Jurowski; Maciej Banach; Jacek Rysz; Aleksander Goch
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

10.  Prediction of perioperative cardiac events through preoperative NT-pro-BNP and cTnI after emergent non-cardiac surgery in elderly patients.

Authors:  Jinling Ma; Qian Xin; Xiujie Wang; Meng Gao; Yutang Wang; Jie Liu
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.